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drKarenousey,readerinAdvancingclinicalPractice,
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The	Department	of	Health	(DH)	(2009a;	b;	2010a;	b)	has	clearly	
identified	the	importance	of	maintaining	and	developing	a	quality	
service	to	all	health	and	social	care	users.	The	QIPP	agenda;	Quality,	
Innovation,	Productivity	and	Prevention	relates	well	to	the	specialities	
of	tissue	viability	and	wound	care.	Integral	to	maintaining	and	
developing	quality	is	the	ethos	‘No	decision	about	me	without	me’	
promoted	in	Equity and Excellence: Liberating the NHS	(DH,	2010a)	
that	suggests	patients	should	be	involved	in	the	decision-making	
process	alongside	practitioners.	Indeed,	patients	will	be	in	charge	of	
making	decisions	about	their	care	and	will	be	able	to	choose	which	
consultant-led	team,	general	practitioner	and	treatment	they	have.	
The	patients’	experience	and	satisfaction	will	be	analysed	through	
the	use	of	Patient	Reported	Outcomes	Measures	(PROMs)	and	the	
amount	of	complaints	received	by	healthcare	users.	
The	importance	of	being	able	to	ensure	that	care	administered	to	
patients	is	based	on	the	best	available	evidence,	and	is	cost	effective	
has	never	been	more	significant,	with	the	DH	(2010a)	identifying	that	
the	NHS	must	make	efficiency	savings	of	between	£15-£20	billion	by	
the	end	of	2013/14.	In	relation	to	tissue	viability,	Posnett	and	Franks	
(2008)	had	calculated	that	200 000	people	in	the	UK	have	a	chronic	
wound	with	an	estimated	cost	of	treatment	being	£2.3–£3.1billion	
per	year,	these	numbers	will	no	doubt	rise	over	the	next	few	years	as	
the	ageing	population	increases.
The	cost	of	preventing	and	treating	pressure	ulcers	in	a	600-bed	
acute	trust	has	been	estimated	as	being	between	£600 000	and	
£3million	a	year	(Touche,	1993).	In	2010	the	DH	(2010b),	estimated	
the	cost	of	a	category	3	pressure	ulcer	as	being	between	£363 000	
to	£543 000	and	a	category	4	pressure	ulcer	as	costing	between	
£447 000	and	£668 000.	They	identified	that	a	reduction	of	25%	in	
pressure	ulcers	would	mean	88	fewer	pressure	ulcers	and	a	potential	
cost	saving	of	£510 000	in	health	care	per	year,	per	NHS	trust.	Many	
pressure	ulcers	are	preventable	through	risk	assessment	and	the	
implementation	of	pressure-relieving	measures	with	the	DH	
promising	that	there	would	be	‘safer	care	for	patients,	who	can	be	
confident	that	they	will	be	protected	from	avoidable	harm’	(DH,	
2009a:29).	This	can	only	happen	if	health	professionals	are	provided	
with	evidence	that	supports	the	use	of	wound	dressings;	education	
to	develop	their	own	knowledge	and	the	skills	to	evaluate	and	
INTRODUCTION
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AIM OF THE EVALUATION
The	overall	aim	of	the	series	of	case	studies	is	to	provide	clinical	
information	on	the	usability,	acceptability	and	clinical	performance	of	
the	ActivHeal®	range	of	products,	when	used	in	the	management	of	
chronic	wounds	of	various	aetiologies.	
understand	the	results	of	audit;	reliability	and	validity	of	evidence	and	
research	presented	to	justify	the	use	of	wound	care	products.	
Horkan	et	al	(2009)	explored	whether	or	not	systematic	reviews,	
undertaken	during	the	period	1998-2008,	focusing	on	the	issue	of	
standard	advanced	wound	dressings,	added	to	the	body	of	
knowledge	in	wound	dressings.	They	identified	13	systematic	reviews	
and	meta-analysis	studies	concluding	that	‘it	appears	that	consistent	
evidence	that	any	one	moist	wound	healing	dressing	is	better	than	
another	in	terms	of	wound	healing	is	still	lacking’	(Horkan	et	al,	2009:	
304).	Nelson	and	Bradley’s	(2007)	review	of	the	Cochrane	database	
exploring	dressings	and	topical	agents	for	arterial	leg	ulcers,	identified	
that	there	was	no	evidence	to	allow	any	recommendations	to	be	made	
on	the	choice	of	dressing	type	or	topical	agent.
A	3-month	‘in-use’	trial	of	the	ActivHeal®	dressings	was	undertaken	
by	Lewis	(2009)	to	ascertain	the	amount	of	money	that	could	be	
saved	if	the	Trusts’	current	choice	of	wound	dressings	were	replaced	
by	those	from	the	ActivHeal®	range.	ActivHeal®	dressings	were	
evaluated	on	care	of	older	people,	surgical,	orthopaedic	and	
neurology	wards	replacing	the	current	foam,	alginate,	gel	and	
hydrocolloid	dressings	on	the	chosen	wards.	At	each	dressing	
change,	the	nurse	was	required	to	fill	out	an	evaluation	form,	at	the	
end	of	one	calendar	month	the	completed	evaluation	forms	were	
collected	and	each	product	was	given	an	evaluation	result	as	being	
either	‘worse	than’,	‘equivalent	to’,	or	‘better	than’	the	previously	
used	dressing.	In	terms	of	dressing	performance,	there	was	no	
obvious	difference	between	the	original	‘branded’	dressings	and	the	
replacement	ActivHeal®	range.	The	ActivHeal®	dressings	were	rated	
as	‘equivalent	to’	or	‘better	than’	original	dressings	in	almost	all	
cases.	The	nursing	staff	registered	no	complaints	about	the	change	
to	the	ActivHeal®	range	of	dressings.
Following	completion	of	the	trial	Lewis	estimated	that	the	annual	cost	
saving	on	foam	dressings	alone	was	in	excess	of	£41 000.	The	annual	
spend	on	wound	dressings,	prior	to	using	ActivHeal®,	was	£103 029,	
the	equivalent	of	3	month	spend,	when	using	ActivHeal®	range	was	
£11 952	which	equated	to	an	annual	spend	of	£47 808.	Lewis	
acknowledges	that	this	trial	was	only	run	over	a	limited	period	of	time	
and	therefore	the	findings	may	not	be	as	accurate	as	a	longer	trial.
This	supplement	presents	a	series	of	case	studies	using	the	
ActivHeal®	range	of	products;	foam	non-adhesive;	foam	adhesive;	
alginate;	aquafiber;	hydrocolloid	and	hydrogel	dressings.	The	
methodology	and	patient	sample	will	be	expanded	in	the	
methodology	section.	The	case	studies	highlight	and	discuss	the	use	
of	the	product	range	and	the	results	that	were	experienced	by	the	
practitioners	and	patients.	A	variety	of	wounds	were	used	to	evaluate	
the	product	range	with	results	showing	that	the	products	worked	
effectively;	were	cost	effective;	comfortable	to	the	patient;	easy	to	
use	and	caused	little	discomfort	on	removal.	
In	the	current	health	economic	climate,	cost	savings	are	essential	for	
each	health	professional	and	commissioner,	without	reducing	the	
quality	of	care	offered	to	each	patient.	The	case	studies	presented	in	
this	booklet	discuss,	highlight	and	present	a	range	of	dressings	that	
can	provide	a	cost-effective	dressing	range	that	are	evaluated	by	
practitioners	and	patients	positively.	
It	is	the	aim	of	this	series	of	evaluations	to	show	progression	of	
healing	in	all	cases,	irrespective	of	the	healing	variables	and	the	
setting	of	care.
ActivHeal® Foam Adhesive ActivHeal® Hydrocolloid
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METHODOLOGy SUMMARy
theevaluationreviewedtheuseoftheActivheal®dressingsin
upto11patientsperproductsection.Patientswererecruited
fortheevaluationfromtheadult(>18years)populationwho
wereroutinelyseenbytheevaluatingclinicians.theresults
werebasedonsubjectivedatacollectedbytheclinicianswho
tookpartintheevaluation.
Patients	were	included	on	the	basis	of	having	a	wound	that	was	
suited	to	the	product	in	accordance	with	the	indications	and	
contraindications	in	the	‘	instruction	for	use’	leaflet	for	each	product.
The	decision	to	treat	the	patient	with	the	ActivHeal®	dressing	was	
made	before	the	patient	was	considered	for	inclusion	in	the	evaluation	
and	following	a	full	wound	assessment.	The	patients’	care	was	not	
affected	and	the	wound	dressing	chosen	was	the	most	suitable	
following	the	patients’	assessment.	The	Trust’s	standard	practice	of	
patient	assessment	and	treatment	was	followed	throughout	the	
evaluation.	Each	dressing	was	applied	and	changed	following	a	
wound	assessment	by	the	registered	practitioner	and	as	required	by	
the	patient’s	need	or	as	dictated	by	the	level	of	exudate,	maintaining	
good	wound	care	practice	according	to	the	Trust’s	standard	of	
practice.	The	ActivHeal®	dressing	was	used	as	a	primary	or	secondary	
dressing	to	suit	the	wound	variables	and	in	accordance	with	Trust	
policy.	Table 1	provides	guidance	on	which	ActivHeal®	dressings	are	
appropriate	for	each	wound	type
Consent	was	given	by	patients	before	inclusion	within	the	evaluation.	
Consent	was	also	gained	to	have	photographs	taken	and	published.	
No	further	ethical	approval	was	required	as	the	use	of	the	product	
was	classed	as	an	evaluation.
The	assessment	of	the	ActivHeal®	products	were	conducted	in	the	
form	of	a	series	of	evaluations	that	included	dressing	changes.	The	
evaluations	were	completed	by	the	relevant	tissue	viability	nurse	who	
attended	the	patient	at	each	dressing	change.	During	each	dressing	
change	the	tissue	viability	nurse	consulted	with	the	attending	nurse	
and	patient	regarding	the	progression	of	the	wound;	amount	of	
exudate,	level	of	pain	experienced	during	dressing	change	and	the	
ease	of	use	of	each	dressing.	The	assessment	of	the	wound	was	
documented	using	data	collection	and	evaluation	forms	provided	by	
Advanced	Medical	Solutions	Ltd.	This	enabled	the	data	gathered	to	
be	collated	to	provide	clinical	evidence	relating	to	the	use	and	
performance	of	the	ActivHeal®	dressing	range	in	clinical	practice;	
progression	of	the	wound	and	the	achievement	of	patient	outcomes.	
The	patient	was	also	asked	to	give	their	opinion	on	how	the	dressing	
felt	throughout	its	weartime	and	if	it	caused	any	discomfort	on	
removal.	Their	comments	were	noted	throughout	the	data	collection.
The	evaluation	parameters/considerations	that	were	applied	are:
•	 Ability	to	manage	exudate
•	 Conformability
•	 Maintaining	moist	wound	environment
•	 Ease	of	use
•	 Overall	rating
•	 Assessment	of	wound	bed/wound	progression.
Wound	type	 Clinical	considerations Expected	outcomes
Product	category	
(primary	dressing)
ActivHeal®	product
Case	study	page	
reference	
Necrotic
If	clinically	relevant,	
removal	of	necrotic	
tissue	–	barrier	to	
healing
Clean,	viable	wound	
bed	free	of	necrotic	
tissue
Hydrogel ActivHeal®	Hydrogel 14
Sloughy
Removal	of	sloughy	
tissue	–	barrier	to	
healing
Clean,	viable	wound	
bed	free	of	sloughy	
tissue
Hydrocolloid,	
Alginate,	
Aquafiber
ActivHeal®	Alginate,	
ActivHeal	Aquafiber®	
ActivHeal®Hydrocolloid,	
7,	8,	12
Highly	exuding
Manage	excess	
exudate.	Identify	cause	
of	excess	exudate	
Exudate	could	macerate	
peri-wound	area
Reduction	in	exudate	
volume
Foam,	Alginate,	
Aquafiber
ActivHeal®	Alginate,	
ActivHeal	Aquafiber®	
ActivHeal®	Foam
7,	8,	10
Granulating
Protect	the	fragile	
granulating	tissue	
Stimulate	growth
Healthy	looking	
granulating	tissue	
Epithelialising	wound
Foam ActivHeal®	Foam
10
Epithelialising	
Maintain	and	protect	
epithelial	tissue
Healed	wound	 Hydrocolloid ActivHeal®	Hydrocolloid 12
Table 1: Appropriate dressing selection when considering ActivHeal® wound care range
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ACTIVHEAL® ALGINATE RESULTS
corrineedwards,tissueviabilitynurseandJodie
Jordan,tissueviabilitynurse,theroyal
Wolverhamptonhospitalsnhstrust
The	results	gained	from	the	dressing	assessment	of	the	ActivHeal®	
Alginate	dressing	range	were	collated	and	analysed.
Seven	patient’s	wounds	were	evaluated	with	the	following	wound	types:
•	 Dehisced	post-C-section	surgical	wound
•	 Pilonidal	sinus
•	 Fungating	breast	wound	
•	 Leg	ulcer	x2
•	 Post-operative	right	above-knee	amputation
•	 Pressure	ulcer	category	4	right	hip.
Patient	progress	was	monitored	and	photos	and	assessments	were	
taken	at	each	dressing	change	to	illustrate	how	the	wounds	had	
progressed	using	the	ActivHeal®	Alginate.
The	seven	patients	comprised	of	four	males	and	three	females,	the	
exudate	levels	of	the	wounds	were	assessed	to	be	between	medium	
and	very	high	across	the	seven	patients.	On	average	the	dressings	
were	changed	every	1-3 days	dependent	on	the	exudate	levels.	In	all	
seven	cases	the	ActivHeal®	Alginate	was	used	as	a	primary	dressing	
and	the	secondary	dressing	was	mainly	the	ActivHeal®	Foam	dressing.
The	data	was	analysed	and	is	shown	in	Figure 1.
The	evaluation	of	the	data	showed	that	in	the	case	of	ActivHeal®	
Alginate’s	ability	to	manage	exudate;	85%	of	the	respondents	were	
very	satisfied,	26%	satisfied	and	none	dissatisfied.	The	staff	reported	
that	the	ActivHeal®	Alginate	managed	the	exudate	well.
In	maintaining	a	moist	environment	80%	were	very	satisfied,	15%	
satisfied	and	none	dissatisfied.	Alginate	fibres	allow	exudate	to	be	
absorbed	into	the	dressing	to	form	a	cohesive	gel,	this	ensures	that	
the	wound	stays	moist	to	provide	an	ideal	wound	healing	environment	
(Winter,	1962).	With	regards	to	conformability	of	ActivHeal®	Alginate,	
81%	were	very	satisfied	and	19%	satisfied.	The	dressing	was	also	
assessed	for	ease	of	use;	86%	were	very	satisfied	and	14%	satisfied.	
It	was	also	documented	on	the	assessment	forms	that	ActivHeal®	
Alginate	was	both	easy	to	apply	and	remove	and	did	not	cause	any	
underlying	trauma	to	the	surrounding	skin	of	the	wound.	The	staff	also	
reported	that	the	dressing	did	not	break	up	on	removal	unlike	some	
other	alginates	that	they	had	used	previously.
The	ActivHeal®	Alginate	is	a	soft,	conformable,	absorbent	dressing.	
In	contact	with	wound	exudate,	ActivHeal®	Alginate	converts	to	a	
soft	gel	that	provides	an	ideal	moist	wound	environment	that	
supports	the	wound	healing	process	and	aids	autolysis	(Beldon,	
2010).	It	is	indicated	for	moderately	to	heavily	exuding	wounds	and	
to	control	minor	bleeding	in	superficial	wounds.	It	was	reported	that	
in	the	case	of	the	fungating	breast	wound	bleeding	was	controlled	
through	the	use	of	the	ActivHeal®	Alginate.	Alginate	fibres	are	a	
natural	haemostat	and	therefore	can	be	used	to	control	minor	
bleeding	(Thomas,	2000).
Anecdotally,	the	patients	also	reported	that	the	dressings	were	
comfortable	when	in	place	and	were	removed	with	ease	and	without	
discomfort.	The	high	wet	strength	of	the	ActivHeal®	Alginate	ensures	
the	dressing	remains	integral	on	removal.	
Overall,	85%	of	the	respondents	were	very	satisfied	and	15%	
satisfied	with	the	product.	This	suggests	that	patients	with	wounds	
of	varying	exudate	levels	will	have	a	positive	experience	when	
ActivHeal®	Alginate	is	used.	All	of	the	wounds	assessed	and	
evaluated	progressed	through	the	healing	continuum	(Gray	et	al,	
2006),	reducing	in	size	and	displaying	a	reduction	in	levels	of	
devitalised	tissue.	
Figure 1. Data from the ActivHeal® Alginate study
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ACTIVHEAL AqUAFIbER® RESULTS
carolynnesinclair,tissueviabilitynurse,countessof
chesternhsfoundationtrust,chester
The	results	gained	from	the	dressing	assessment	of	the	ActivHeal	
Aquafiber®	dressing	range	were	collated	and	analysed.
Ten	patient’s	wounds	were	evaluated	with	the	following	wound	types:
•	 Dehisced	post-laporatomy	surgical	wound
•	 Leg	ulcers	x3
•	 Pressure	ulcer	category	4	sacrum	x3	
•	 Cellulitis
•	 Pressure	ulcer	caused	by	bandage	damage
•	 Pressure	ulcer	category	4	buttock.
Patient	progress	was	monitored	and	photos	and	assessments	were	
taken	at	each	dressing	change	to	illustrate	how	the	wounds	had	
progressed	using	the	ActivHeal	Aquafiber®.
The	ten	patients	comprised	of	three	males	and	seven	females,	the	
exudate	levels	of	the	wounds	were	assessed	to	be	between	medium	
and	very	high	across	the	ten	patients.	On	average	the	dressings	
were	changed	every	1-3	days	dependent	on	the	exudate	levels.	In	all	
ten	cases	the	ActivHeal	Aquafiber®	was	used	as	a	primary	dressings	
and	the	secondary	dressing	was	mainly	the	ActivHeal®	Foam	
dressing.	The	data	was	analysed	and	is	shown	in	Figure 2.
The	evaluation	of	the	data	showed	that	in	the	case	of	ActivHeal	
Aquafiber®’s	ability	to	manage	exudate;	74%	of	the	responses	were	
very	satisfied,	26%	satisfied	and	none	dissatisfied.
In	maintaining	a	moist	environment	80%	were	very	satisfied,	20%	
satisfied	and	no	dissatisfied.	In	regards	to	ActivHeal®Aquafiber’s	
conformability,	80%	were	very	satisfied	and	20%	satisfied.	The	
product	was	also	assessed	for	ease	of	use;	83%	were	very	satisfied	
and	17%	satisfied.	It	was	also	documented	on	the	assessment	
forms	that	ActivHeal	Aquafiber®	was	both	easy	to	apply	and	remove	
and	did	not	cause	any	underlying	trauma	to	either	the	surrounding	
skin	of	the	wound	or	through	maceration	to	the	peri-wound	area,	a		
result	of	the	reduced	lateral	wicking	capability	of	ActivHeal	
Aquafiber®.	
Anecdotally,	the	patients	also	reported	that	the	dressings	were	
comfortable	when	in	place	and	were	removed	with	ease	and		
without	discomfort.
Overall,	80%	of	the	respondents	were	very	satisfied	and	20%	
satisfied	with	the	product.	This	suggests	that	patients	with	wounds	
of	varying	exudate	levels	will	have	a	positive	experience	when	
ActivHeal	Aquafiber®	is	used.	In	all	of	the	wounds	assessed	and	
evaluated	the	wounds	progressed	through	the	healing	continuum	
(Gray	et	al,	2006),	with	all	of	the	ten	wounds	reducing	in	size	and	
level	of	devitalised	tissue.	One	of	the	wounds	progressed	through	
the	wound	healing	continuum	despite	having	not	shown	any	signs	of	
healing	for	over	a	year.
CASE STUDy
Mr	T	was	an	87-year-old	male	with	a	history	of	angina.	The	patient	
was	admitted	with	bilateral	leg	ulcers	which	had	been	present	for	
5 years	(Figure 3).	He	was	admitted	as	an	emergency	for	a	possible	
angioplasty	and	a	possible	amputation.	The	patient	was	also	on	
nicorandil	for	his	angina.
	
INITIAL PRESENTATION
At	the	initial	examination	the	wound	presented	as	an	area	of	thick	
adherent	slough	with	a	high	amount	of	exudate.	The	wound	was	very	
malodorous	and	painful	for	Mr	T.	He	was	referred	to	the	tissue	viability	
nurse	who,	on	initial	assessment,	felt	that	some	of	the	complications,	
including	an	anal	ulceration,	may	be	because	of	his	medication	
Figure 2. Data from the ActivHeal Aquafiber® assessment Figure 3. Mr T’s leg at presentation
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(nicorandil)	(McKenna	et	al,	2007).	Nicorandil	is	a	vasodilatory	drug	used	
to	treat	angina.	It	is	used	to	maintain	blood	flow	to	the	heart	and	prevent	
angina	pain.	Some	of	the	side	effects	noted	for	this	drug	are	skin	and	
mucosal	ulcers.	There	has	also	been	research	that	has	reported	
ulceration	at	sites	including	lower	anterior	leg	ulcer	(McKenna	et	al,	
2007).	Therefore,	with	the	initial	assessment,	the	patient’s	medication	
was	also	changed	and	he	commenced	on	reducing	nicorandil.
The	wound	was	initially	sharp	debrided	to	remove	any	loose	debris.
The	priority	for	this	wound	was	the	continued	removal	of	devitalised	
tissue	through	the	facilitation	of	autolytic	debridement,	and	the	
management	of	exudate	while	maintaining	a	moist	wound	
environment.	ActivHeal	Aquafiber®	was	chosen	to	assist	in	the	
facilitation	of	autolysis	of	the	devitalised	tissue	and	manage	the	
exudate	levels.	The	ActivHeal	Aquafiber®	is	a	soft,	conformable,	
highly	absorbent	dressing.	In	contact	with	wound	exudate	ActivHeal	
Aquafiber®	converts	to	a	soft,	clear	gel	providing	an	ideal	moist	
wound	environment	that	supports	the	wound	healing	process.	It	is	
indicated	for	moderately	to	heavily	exuding	wounds	and	to	control	
minor	bleeding	in	superficial	wounds	(Hawkins,	2010).
The	secondary	dressing	that	was	used	was	ActivHeal®	Non	Adhesive	
Foam	which	was	chosen	to	assist	in	managing	the	high	levels	of	
exudate	and	maintaining	a	moist	wound	environment.	The	‘top	film’	
of	ActivHeal®	Non	Adhesive	Foam	also	provided	a	bacterial	barrier	to	
assist	in	the	prevention	of	infection	and	contamination.	The	dressings	
were	further	secured	using	wool	and	crepe	from	toe	to	knee.	Mr	T	
was	also	commenced	on	intravenous	antibiotics	as	he	was	
diagnosed	with	a	group	A	streptococcal	infection.
	
Dressing	changes	took	place	daily;	Figure 4	shows	the	wound	
following	two	days	of	treatment.	The	wound	had	started	to	debride	
autolytically	with	the	application	of	the	ActivHeal	Aquafiber®	and	
ActivHeal®	Foam	dressings.	The	wound	had	areas	of	granulation	and	
ActivHeal	Aquafiber®	had	managed	the	exudate	successfully	as	there	
was	no	peri-wound	maceration.	The	wound	was	reassessed	and	
ActivHeal	Aquafiber®	was	continued.	
	
The	wound	continued	to	progress	through	the	healing	continuum,	
and	at	all	times	the	peri-wound	area	remained	intact	with	no	signs	of	
maceration	(Figure 5).
	
A	further	5	days	later	following	daily	applications	of	ActivHeal	Aquafiber®	
the	wound	continued	to	improve	(Figure 6).	All	slough	had	been	
removed	and	the	wound	was	fully	granulating.	The	peri-wound	
remained	intact	and	there	were	no	signs	of	maceration.	There	was	also	
evidence	of	new	epithelising	tissue.	At	this	point	the	patient	also	went	
for	an	angioplasty.	A	few	days	later	the	patient	was	discharged	home.
The	main	challenge	with	this	wound	was	to	effectively	remove	the	
sloughy	tissue	and	maintain	a	moist	wound	healing	environment	
while	also	managing	the	wound	exudate.	Both	the	ActivHeal	
Aquafiber®	and	ActivHeal®	Foam	enabled	the	wound	to	progress	
through	the	wound	healing	continuum	(Gray	et	al,	2006),	following	
initial	sharp	debridement.	The	products	demonstrated	good	clinical	
outcomes	while	allowing	easy	dressing	removal	without	causing	pain	
and	trauma	to	the	patient	on	removal.	It	should	also	be	noted	that	
the	removal	of	nicorandil	from	Mr	T’s	medication	appeared	to	be	an	
aetiological	factor	of	the	leg	ulcers	which	improved	following	its	
discontinuation.	This	would	have	assisted	in	the	wound’s	
improvement	along	with	administration	of	intravenous	antibiotics.
DISCUSSION 
The	performance	of	ActivHeal	Aquafiber®	demonstrated	by	the	results	
and	the	case	study	are	encouraging.	The	evaluation	showed	that	the	
ActivHeal	Aquafiber®	is	an	effective	wound	care	choice	that	has	shown	
good	management	of	exudate	and	created	the	right	environment	for	
healing	and	wound	progression.	This	is	demonstrated	by	the	fact	that	all	
the	patients	within	the	study	showed	signs	of	healing	and	wound	
progression.	Eighty	percent	of	respondents	were	very	satisfied	and	20%	
satisfied	with	the	overall	performance	of	the	dressing.	
The	outcome	of	the	study	suggests	that	patients	with	chronic	
wounds	will	have	a	positive	experience	when	ActivHeal	Aquafiber®	is	
used.	This	is	because	it	has	the	required	attributes	of	an	absorbent	
fibre	dressing	for	use	on	a	range	of	chronic	wounds.
Figure 4. Mr T’s leg following two days of treatment
Figure 5. Four days after the application of ActivHeal Aquafiber®
Figure 6. Five days after the application of ActivHeal Aquafiber®
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The	results	gained	from	the	dressing	assessment	of	the	ActivHeal®	
Foam	dressing	range	were	collated	and	analysed.
Eleven	patients’	wounds	were	evaluated	with	the	following	wound	types:
•	 Pre-tibial	laceration	x5
•	 Evacuated	haematoma	
•	 Dehisced	post-surgical	wound	to	ankle
•	 Bitumen	burn	to	foot
•	 Pressure	ulcer	to	medial	aspect	of	ankles
•	 Pressure	ulcer	to	sacrum
•	 Dehisced	post-cardiac	surgical	wound.
Patient	progress	was	monitored	and	photos	and	assessments	were	
taken	at	each	dressing	change	to	illustrate	how	the	wounds	had	
progressed	using	the	ActivHeal®	Foam.
The	11	patients	comprised	of	six	males	and	five	females,	the	
exudate	levels	of	the	wounds	were	assessed	between	low	to	
medium	levels	of	exudate.	On	average	the	dressings	were	changed	
every	3-4 days.	In	all	11	cases	the	ActivHeal®	Foam	was	used	as	a	
primary	dressing.	The	case	study	presents	a	male	admitted	with	a	
dog	bite	wound	that	was	initially	treated	with	a	hydrogel	and	foam.	
However,	on	week	two	the	hydrogel	was	discontinued	and	the	
ActivHeal®	foam	dressing	used	as	a	primary	dressing	and	was	not	
included	in	the	initial	evaluations.The	data	was	analysed	and	is	
shown	in	Figure 7.
The	evaluation	of	the	data	showed	that	in	the	case	of	ActivHeal®	
Foam’s	ability	to	manage	exudate,	90%	of	the	respondents	were	
very	satisfied,	8%	satisfied	and	only	2%	dissatisfied.
In	maintaining	a	moist	environment	93%	were	very	satisfied,	5%	
satisfied	and	only	2%	dissatisfied.	It	was	documented	that	one	
patient	(representing	the	2%	dissatisfied)	noted	their	skin	had	
become	slightly	macerated	owing	to	a	sudden	increase	in	exudate	
leading	to	an	increase	in	dressing	changes	until	exudate	levels	
subsided.	
When	asked	about	ActivHeal®	Foam’s	conformability,	71%	were	very	
satisfied	and	29%	satisfied.	The	product	was	also	assessed	for	ease	
of	use	where	98%	were	very	satisfied	and	2%	dissatisfied.	
Documentation	on	the	assessment	forms	identified	that	ActivHeal®	
Foam	was	both	easy	to	apply	and	to	remove	and	did	not	cause	any	
underlying	trauma	to	either	the	surrounding	skin	of	the	wound	or	
through	maceration	to	the	peri-wound	area.	One	patient	noted	that	
the	dressing	had	become	dislodged,	however,	the	patient	had	
applied	Epaderm	ointment	to	dry	skin	prior	to	the	use	of	the	
dressing,	which	may	have	caused	the	dressing	to	become	
dislodged.	
Anecdotally,	the	patients	also	reported	that	the	dressings	were	
comfortable	when	in	place	and	were	removed	with	ease	and		
without	discomfort.
An	overall	rating	of	93%	of	the	respondents	were	very	satisfied	and	
7%	satisfied	with	the	product,	this	suggests	that	patients	with	a	
range	of	wounds	of	varying	exudate	levels	will	have	a	positive	
experience	whenActivHeal®	Foam	is	used.	All	of	the	wounds	
progressed	through	the	healing	continuum	(Gray	et	al,	2006),	with	a	
number	of	wounds	reducing	in	size	and	level	of	devitalised	tissue,	
and	one	of	the	wounds	completely	healed.
CASE STUDy: USING ACTIVHEAL® FOAM TO MANAGE 
ExUDATE AS A SECONDARy DRESSING
Mr	P	was	a	56-year-old	male	with	a	history	of	a	previous	deep	vein	
thrombosis	and	a	non-insulin-dependent	diabetic	of	4 years.	The	
patient	had	presented	to	Accident	and	Emergency	with	chest	pain.	
On	admission	it	was	noted	that	the	patient	had	a	wound	to	his	right	
thigh.	The	cause	of	the	wound	was	a	dog	bite	4	months	previously	
that	he	was	self-treating	with	an	antiseptic	cream	and	dry	dressing	
(Figure 8).
INITIAL PRESENTATION
At	the	initial	examination	the	wound	presented	as	an	area	of	
adherent	slough	with	little	exudate.	The	peri-wound	area	seemed	
Figure 7. Data from the ActivHeal® Foam assessment
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fragile	with	some	oedema.	There	was	also	evidence	of	some	
healed	tissue.	The	priority	for	this	wound	was	to	debride	the	
devitalised	tissue	through	rehydration	and	the	facilitation	of	
autolytic	debridement.	ActivHeal®	Hydrogel	was	chosen	to	assist	in	
the	rehydration	of	the	wound,	to	remove	the	devitalised	tissue	and	
facilitate	autolysis.	The	secondary	dressing	that	was	used	was	
ActivHeal®	Foam	Adhesive	which	was	chosen	to	ensure	the	
hydrogel	remained	in	place,	while	maintaining	a	moist	wound	
environment.	The	ActivHeal®	Foam	Adhesive	also	provided	a	
bacterial	barrier	to	prevent	infection	and	contamination	but	also	
enabled	the	patient	to	wash	and	shower	as	the	dressing	is	
waterproof.	The	ActivHeal®	Foam	has	a	range	of	features	which	
ensure	that	excess	exudate	is	absorbed	away	from	the	wound	bed,	
and	a	moist	healing	environment	maintained	to	create	a	wound	
healing	environment.	
Dressing	changes	took	place	every	2-3	days.	The	wound	continued	
to	debride	autolytically	with	the	application	of	the	ActivHeal®	
Hydrogel	and	ActivHeal®	Foam	Adhesive	dressings.	Following	a	
week	of	this	dressing	regime,	which	accounted	for	two	dressings	
changes,	the	ActivHeal®	Hydrogel	was	discontinued	as	all	of	the	
devitalised	tissue	had	been	removed	and	the	exudate	levels	had	
increased.	At	this	point	the	wound	was	reassessed	and	ActivHeal®	
Foam	Adhesive	was	chosen	to	effectively	absorb	and	retain	the	
exudate,	maintain	a	moist	environment,	facilitate	moist	wound	
healing	and	prevent	contamination.
The	wound	continued	to	progress	through	the	healing	continuum,	
and	at	all	times	the	peri-wound	area	remained	intact	with	no	signs	of	
maceration	which	demonstrated	that	the	ActivHeal®	Foam	Adhesive	
was	managing	the	levels	of	exudate	well.	The	patient	was	
discharged	home	to	the	care	of	the	district	nurses	(Figure 9).
	
To	conclude,	the	main	challenge	was	to	effectively	rehydrate	the	
sloughy	tissue	and	maintain	a	moist	wound	healing	environment.	
Both	the	ActivHeal®	Hydrogel,	ActivHeal®	Foam	Adhesive	along	with	
ActivHeal®	Foam	Non	Adhesive	allowed	the	wound	to	progress.	
The	products	demonstrated	good	clinical	outcomes	while	allowing	
easy	dressing	usage	without	causing	pain	and	trauma	to	the	patient	
on	removal.
DISCUSSION 
The	performance	of	ActivHeal®	Foam	demonstrated	by	the	results	
and	the	case	study	are	encouraging.	The	evaluation	showed	that	the	
ActivHeal®	Foam	has	demonstrated	effective	management	of	
exudate	and	created	the	right	environment	for	healing	and	wound	
progression.	Ninety-three	percent	of	respondents	were	very	satisfied	
with	the	overall	performance	of	the	dressing.	
The	outcome	of	the	study	suggests	that	ActivHeal®	Foam	can	be	
used	on	a	range	of	chronic	wounds.	Chronic	wounds	are	defined	by	
Collier	(2002)	as:	‘wounds that	are	failing	to	heal	as	anticipated	or	
that	have	become	fixed	at	any	one	phase	of	wound	healing’.
Figure 8. Mr P’s wound at presentation Figure 9. Wound on discharge, 3 weeks following initial assessment
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The	results	gained	from	the	dressing	assessment	of	the	ActivHeal®	
Hydrocolloid	dressing	range	were	collated	and	analysed.
Ten	patient’s	wounds	were	evaluated	with	the	following	wound	types:
•	 Traumatic	wound	x2
•	 Category	2	pressure	ulcer	x4
•	 Leg	ulcer	x3	
•	 Superficial	dermal	burn.
Patient	progress	was	monitored	and	photos	and	assessments	were	
taken	at	each	dressing	change	to	illustrate	how	the	wounds	had	
progressed	using	the	ActivHeal®	Hydrocolloid.
The	ten	patients	comprised	of	six	males	and	four	females,	the	
exudate	levels	of	the	wounds	were	assessed	between	low	to	
medium	levels	of	exudate.	On	average	the	dressings	were	changed	
between	5	and	7	days.	In	all	ten	cases	the	ActivHeal®	Hydrocolloid	
was	used	as	a	primary	dressing.	The	data	was	analysed	and	is	
shown	in	Figure 10.
The	evaluation	of	the	data	showed	that	in	the	case	of	ActivHeal®	
Hydrocolloid’s	ability	to	manage	exudate,	41%	of	the	responses	
were	very	satisfied	and	59%	were	satisfied.
In	maintaining	a	moist	environment	41%	were	very	satisfied	and	59%	
satisfied.	In	regards	to	ActivHeal®	Hydrocolloid’s	conformability,	35%	
were	very	satisfied	and	65%	satisfied.	The	product	was	also	assessed	
for	ease	of	use,	41%	were	very	satisfied	and	59%	were	satisfied.	It	was	
also	documented	on	the	assessment	forms	that	ActivHeal®	Hydrocolloid	
was	easy	to	apply	and	did	not	cause	any	underlying	trauma	to	either	the	
surrounding	skin	of	the	wound	or	through	maceration	to	the	peri-wound	
area.	It	was	also	documented	that	seven	out	of	the	ten	wounds	healed	
using	the	ActivHeal®	Hydrocolloid.
The	nurses	reported	that	the	dressings	were	able	to	effectively	
remove	devitalised	tissue	of	both	necrosis	and	slough.	The	nurses	
also	reported	that	it	was	effective	in	the	management	of	the	wound	
and	remained	in	place	for	the	recommended	wear	time.	The	patients	
also	reported	that	the	dressing	was	very	comfortable	as	they	had	
forgotten	that	the	dressing	was	on	their	wound.
Overall	41%	of	the	respondents	were	very	satisfied	and	59%	
satisfied	with	the	product,	this	suggests	that	patients	with	wounds	
that	have	been	assessed	to	remove	devitalised	tissue	with	low	to	
medium	exudate	levels	will	have	a	positive	experience	when	
ActivHeal®	Hydrocolloid	is	used.	In	all	of	the	wounds	assessed	and	
evaluated	there	was	progress	through	the	wound	healing	continuum,	
this	resulted	in	the	removal	of	devitalised	tissue	and	the	promotion	of	
wound	healing.
CASE STUDy
Mrs	C	was	an	83-year-old	female.	She	attended	the	wound	care	
clinic	having	dropped	a	hot	cup	of	tea	onto	the	upper	thigh	of	her	left	
leg	(Figure 11).	
INITIAL PRESENTATION
At	the	initial	examination	the	wound	presented	with	both	granulating	
and	epithelial	tissue,	however,	there	was	a	10%	area	of	slough.	The	
patient’s	wound	was	fully	assessed	and	a	superficial	dermal	burn	
was	identified.	
The	priority	for	this	wound	was	to	debride	the	devitalised	tissue	
through	the	facilitation	of	autolytic	debridement.	ActivHeal®	
Hydrocolloid	was	chosen	to	assist	in	the	rehydration	of	the	wound,	
to	remove	the	devitalised	tissue	and	facilitate	autolysis.	The	
ActivHeal®	Hydrocolloid	contains	a	blend	of	synthetic	polymers	and	
hydrophilic	powders	which	provide	a	self-adhesive	absorbent	
material	for	wound	applications.	As	well	as	providing	a	bacterial	
barrier	to	the	wound	site,	the	wound	dressing	also	absorbs	exudate	
to	form	a	cohesive	gel	that	promotes	a	moist	wound	healing	
environment.	Benbow	(2005)	states	that	hydrocolloid	dressings	are	Figure 10. Data from the ActivHeal® Hydrocolloid assessment
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indicated	for	wounds	with	low	to	medium	exudate,	from	which	they	
can	absorb	and	hold	exudate	in	the	hydrocolloid	matrix.	They	are	
completely	impermeable	to	water	and	therefore	support	rehydration	
and	autolytic	debridement	of	necrotic	and	sloughy	wounds.	
The	product	was	also	chosen	to	provide	a	moist	environment	and	
promote	both	granulation	and	epithelisation.	The	ActivHeal®	
Hydrocolloid	would	provide	a	bacterial	barrier	to	prevent	infection	
and	contamination	but	also	enabled	the	patient	to	wash	and	shower	
as	the	dressing	was	waterproof.
The	dressing	was	changed	a	week	later	(Figure 12).	The	wound	had	
started	to	debride	autolytically	with	the	application	of	the	ActivHeal®	
Hydrocolloid.	The	sloughy	tissue	has	started	to	lift	and	there	was	an	
increase	of	granulation	tissue	and	epithelial	tissue	visable	at	the	
wound	edges.	The	same	dressing	regime	was	continued.	
By	week	four	(Figure 13)	the	wound	had	completely	healed	and	the	
dressing	was	discontinued	and	Mrs	C	was	discharged.	Throughout	
the	treatment	of	the	superficial	dermal	burn	the	dressing	was	easy	to	
apply	and	was	conformable.	The	dressing	stayed	in	place	and	was	
easy	to	remove	without	causing	any	trauma	to	the	wound	and	
surrounding	skin.
DISCUSSION 
The	performance	of	ActivHeal®	Hydrocolloid	demonstrated	by	the	
results	and	the	case	study	are	encouraging.	The	evaluation	suggests	
that	the	ActivHeal®	Hydrocolloid	is	an	effective	wound	care	choice	
that	has	shown	effective	removal	of	devitalised	tissue	and	created	
the	right	environment	for	healing	and	wound	progression.	All	the	
patients	within	the	study	showed	signs	of	healing	and	wound	
progression;	41%	were	very	satisfied	and	59%	were	satisfied	with	
the	overall	performance	of	the	dressing.	
The	outcome	of	the	evaluation	study	demonstrated	that	ActivHeal®	
Hydrocolloid	possesses	the	required	attributes	of	a	hydrocolloid	
dressing	for	usage	on	a	range	of	both	acute	and	chronic	wounds.
Figure 11. Mrs C’s wound on presentation
Figure 12. Mrs C’s wound at week 2
Figure 13. Mrs C’s wound at week 4
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The	results	gained	from	the	dressing	assessment	of	the	ActivHeal®	
Hydrogel	dressing	range	were	collated	and	analysed.
Eleven	patients’	wounds	were	evaluated	with	the	following		
wound	types:
•	 Necrotic	pressure	ulcers	x6
•	 Devitalised	tissue	following	forefoot	amputation
•	 Pressure	ulcer	left	hip	category	3
•	 Grade	4	pressure	ulcer	sacrum	x2
•	 Dehisced	abdomen	with	dry	necrosis.
Patient	progress	was	monitored	and	photos	and	assessments	were	
taken	at	each	dressing	change	to	illustrate	how	the	wounds	had	
progressed	using	ActivHeal®	Hydrogel.
The	11	patients	comprised	of	six	males	and	five	females,	the	
exudate	levels	of	the	wounds	were	assessed	between	dry	to	low	
levels	of	exudate.	On	average	the	dressings	were	changed	either	
every	day	or	on	alternate	days.	In	all	11	cases	the	ActivHeal®	
Hydrogel	was	used	as	a	primary	dressings	and	ActivHeal®	Foam	
dressing	was	used	as	a	secondary	dressing.The	data	was	analysed	
and	is	shown	in	Figure 14.
In	maintaining	a	moist	environment	71%	were	very	satisfied,	25%	
satisfied	and	only	4%	dissatisfied.	In	regards	to	ActivHeal®	Hydrogel’s	
conformability,	75%	were	very	satisfied	and	25%	satisfied.	All	
respondents	were	very	satisfied	with	the	product’s	ease	of	use.	It	
was	also	documented	on	the	assessment	forms	that	ActivHeal®	
Hydrogel	had	a	high	viscosity,	was	easy	to	apply	and	did	not	cause	
any	underlying	trauma	to	either	the	surrounding	skin	of	the	wound	or	
through	maceration	to	the	peri-wound	area.	
Anecdotally,	the	nurses	also	reported	that	the	dressings	were	able	to	
effectively	rehydrate	and	remove	devitalised	tissue	of	both	necrosis	
and	slough	and	that	on	three	occasions	only	one	application	of	the	
ActivHeal®	Hydrogel	was	necessary.	The	nurses	also	reported	that	
there	was	minimal	residue	left	on	the	wound	prior	to	reapplication	of	
the	gel,	suggesting	that	the	absorption	of	the	product	had	occurred	
and	a	degree	of	rehydration	had	been	achieved.
An	overall	rating	of	79%	of	the	respondents	were	very	satisfied	and	
21%	satisfied	with	the	product,	which	supports	that	the	product	is	
acceptable	for	wounds	that	have	been	assessed	to	remove	
devitalised	tissue	with	dry	to	low	exudate	levels.	All	of	the	wounds	
assessed	and	evaluated	progressed	through	the	healing	continuum,	
with	devitalised	tissue	being	removed.	
CASE STUDy
Mrs	B	was	a	94-year-old	female	with	a	past	medical	history	of	
diabetes	and	hypotension.	The	patient	was	admitted	following	a	fall	
with	reduced	mobility	and	was	generally	unwell.	On	admission	the	
patient	was	fully	assessed	and	an	area	on	her	right	buttock	was	
discoloured	with	areas	of	necrosis	(Figure 15)	and	the	patient	was	
referred	to	the	tissue	viability	team.
INITIAL PRESENTATION
At	the	initial	examination	the	wound	presented	as	an	area	of		
necrosis	with	little	exudate.	The	cause	of	the	wound	was	pressure	and	
moisture	as	the	patient	was	incontinent	of	both	faeces	and	urine.	The	
patient	was	also	non-concordant	and	refused	to	be	turned	or	tilted.	
However,	she	did	agree	to	be	nursed	on	a	pressure-relieving	mattress.
It	was	difficult	to	assess	the	depth	of	the	tissue	involvement	in	this	
lesion	as	necrotic	eschar	was	present	and	therefore	it	was	decided	
Figure 14. Data from the ActivHeal® Hydrogel assessment Figure 15. Mrs B’s wound on presentation
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debridement	was	required	to	facilitate	a	diagnosis	of	depth.	The	
European	Pressue	Ulcer	Advisory	Panel	(EPUAP)	classification	
system	has	attempted	to	address	the	difficulty	of	categorising	a	
necrotic	lesion	by	using	an	unclassified/unstageable	classification.	
This	descriptive	definition	discusses	it	as	full	thickness	tissue	loss	in	
which	the	actual	depth	of	the	ulcer	is	completely	obscured	by	slough	
and/or	eschar	in	the	wound	bed.	Until	enough	slough/eschar	is	
removed	to	expose	the	base	of	the	wound,	the	true	depth	cannot	be	
determined	(EPUAP,	2009).
The	priority	for	this	wound	was	debridement,	this	was	achieved	
using	a	rehydration	method	that	facilitated	autolytic	debridement.	
ActivHeal®	Hydrogel	was	chosen	to	assist	in	the	rehydration	of	the	
wound,	to	remove	the	devitalised	tissue	and	facilitate	autolysis.	The	
ActivHeal®	Hydrogel	contains	85%	water	and	a	collection	of	
polymer	chains	that	are	water	insoluble	and	is	indicated	for	the	
management	of	necrotic	and	sloughy	wounds	with	nil	to	low		
exudate	including	pressure	ulcers,	cavity	wounds,	leg	ulcers,	skin	
donor	sites	and	diabetic	foot	ulcers.	Hydrogels	donate	moisture	to	
provide	a	moist	environment,	this	encourages	and	facilitates	
autolysis	or	debridement	of	devitalised	tissue	from	the	wound	bed	
(Morris,	2006).	
The	secondary	dressing	that	was	used	was	ActivHeal®	Adhesive	
Foam	which	was	chosen	to	ensure	the	hydrogel	remained	in	place,	
while	maintaining	a	moist	wound	environment.	The	ActivHeal®	
Adhesive	Foam	also	provided	a	bacterial	barrier	to	prevent	infection	
and	contamination	but	also	enabled	the	patient	to	wash	and	shower	
as	the	dressing	is	waterproof.
Dressing	changes	took	place	daily.	The	wound	continued	to	debride	
autolytically	with	the	application	of	the	ActivHeal®	Hydrogel	and	
ActivHeal®	Adhesive	Foam	dressings.	The	necrotic	tissue	started	to	
soften	and	there	were	small	areas	of	granulation	visible	at	the	wound	
edges.	The	same	dressing	regime	was	continued	for	the	duration	of	
week	2	(Figure 16)	and	by	the	end	of	the	week	further	debridement	
and	removal	of	devitalised	tissue	was	evident	(Figure 17).	
By	the	third	week	of	treatment	the	wound	had	been	fully	debrided	of	
devitalised	tissue	(Figure 18).	The	wound	was	producing	higher	levels	
of	exudate,	it	was	reassessed	and	the	treatment	regime	changed	to	
ActivHeal	Aquafiber®	and	ActivHeal®	Foam	Adhesive.	This	was	to	
ensure	that	the	wound	continued	through	the	wound	healing	
continuum	and	to	prevent	any	maceration	to	the	peri-wound	area.
DISCUSSION 
The	performance	of	ActivHeal®	Hydrogel	demonstrated	by	the	results	
and	the	case	study	are	encouraging.	The	evaluation	showed	that	
ActivHeal®	Hydrogel	is	an	effective	wound	care	choice	that	has	
shown	successful	removal	of	devitalised	tissue	and	has	created	the	
right	environment	for	healing	and	wound	progression.	This	is	
demonstrated	by	the	fact	that	all	of	the	patients	within	the	study	
showed	signs	of	healing	and	wound	progression.	Seventy-nine	
percent	of	respondents	were	very	satisfied	and	21%	were	satisfied	
with	the	overall	performance	of	the	product.	
The	outcome	of	the	study	supports	the	usage	of	ActivHeal®	Hydrogel	
and	demonstrated	that	the	product	has	the	required	attributes	of	a	
Hydrogel	dressing	for	use	on	a	range	of	chronic	wounds.
Figure 16. Wound following 7 days of use of ActivHeal® 
Hydrogel
Figure 17. Wound continued to be softened using ActivHeal® 
Hydrogel
Figure 18. Wound at 3 weeks of treatment
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Bolger,	2010)	which	is	to	be	reinvested	so	that	the	burgeoning	care	
deficit	can	be	addressed.	Nurses	are	well	placed	to	be	innovative	by	
examining	process	and	cutting	out	duplication	and	waste.	It	is	
imperative	that	we	benchmark	practices	that	align	to	the	ideals	of	a	
quality,	cost-effective	and	productive	service	which	focuses	on	
safety,	effectiveness	and	patient	experience.	In	relation	to	the	quality	
agenda	there	is	a	need	to	ensure	that	wound	care	products	are	able	
to	assist	the	health	professional	in	the	management	of	wounds.	
Every	dressing	change	will	have	an	impact	on	the	patient	experience;	
therefore,	evidence	outlining	the	effectiveness	of	wound	care	
CONCLUSION
thedepartmentofhealth’squalityAgendaincluding
qIPP(quality,Innovation,Prevention,Productivity)
identifiedandhighlightedtheimportanceofallhealth
professionalsworkingtowardsmaintainingand
developingpatientsafety,patientexperienceandclinical
effectiveness.
Approximately	3%	of	the	NHS	budget	is	spent	on	treating	chronic	
wounds,	costing	the	NHS	£2–3	billion	per	annum,	based	on	an	
estimate	of	200 000	people	in	the	UK	suffering	with	a	chronic	wound	
(Posnett	and	Franks,	2007).	As	the	ageing	population	continues	to	
increase,	the	amount	of	chronic	wounds	will	inevitably	increase,	as	will	
the	cost	to	the	NHS	of	treating	these	wounds.	Interestingly,	Vowden	et	
al	(2009)	undertook	a	local	audit	exploring	the	incidence	of	wounds	
and	suggested	that	approximately	3.55	per	1000	of	the	population	
had	a	wound	of	some	kind.	It	is	therefore	vital	that	practitioners	in	both	
primary	and	secondary	care	are	able	to	access	products	that	meet	the	
needs	of	their	patient’s	wounds	and	are	cost	effective.	
This	clinical	supplement	has	presented	and	evaluated	the	successful	
use	of	ActivHeal®	dressings	on	a	pressure	ulcer,	leg	ulcer,	dog	bite	
and	burn.	All	patients	involved	in	the	evaluations	were	over	18	years	
of	age	and	the	clinicians	evaluating	the	effect	of	the	products	on	the	
wound	healing	continuum	were	all	tissue	viability	nurses.	
Visual	representation	of	the	results	are	presented	in	Graphs	1-5.	
Despite	experiencing	increasing	demand	for	care	and	services,	in	the	
context	of	a	diminishing	income	and	economic	crisis,	the	NHS	has	
been	asked	to	find	£15-20	billion	of	savings	over	4 years	(Foster	and	
Graph 1: ActivHeal® Alginate dressing range
7 patients were recruited for the evaluation of the ActivHeal® 
Alginate range of products.
Graph 2: ActivHeal Aquafiber® dressing range
10 patients were recruited for the evaluation of the ActivHeal 
Aquafiber® dressing
Graph 3: ActivHeal® Foam dressing range
11 patients were recruited for the evaluation of the ActivHeal® 
Foam dressing range
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products	can	support	health	professionals	in	their	roles	to	select	
quality	products	that	assist	in	wound	management.
The	case	study	evaluations	present	excellent	patient	outcomes,	
demonstrating	the	ActivHeal®	wound	care	products’	ability	to	
manage	exudate;	maintain	a	moist	wound	environment;	
conformability	to	the	wound	and	ease	of	use	for	practitioners.	
Graph 4: ActivHeal® Hydrocolloid range
10 patients were recruited for the evaluation of the ActivHeal® 
Hydrocolloid
Graph 5: ActivHeal® Hydrogel dressing range
11 patients were recruited for the evaluation of the ActivHeal® 
Hydrogel dressing
Choosing	the	correct	and	appropriate	dressing	to	manage	a	wound	
is	essential,	with	practitioners	ensuring	that	their	choice	of	product	is	
based	on	the	best	available	evidence	while	ensuring	cost	
effectiveness.	This	supplement	has	presented	case	study	and	
assessment	evidence	which	supports	the	ActivHeal®	range	in	
providing	practitioners	with	products	that	manage	the	complexities	
of	promoting	moist	wound	healing	in	a	cost-effective	manner.	
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